NSE / BSEHealthcare
β‚Ή1042.00-2.00-0.19%
P/E112.0Mkt Capβ‚Ή8.55 K CrEV/EBITDA35.5

STRIDES PHARMA SCIENCE LIMITED

P/E112.0Mkt Capβ‚Ή8.55 K CrEV/EBITDA35.5
Company Profile

Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women's health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. The company was incorporated in 1990 and is based in Bengaluru, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 28 Jul 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–² 12.95% over 1Y
Monthly Returns

Historically, Apr has averaged the highest return (+7.2%); Dec the lowest (-5.7%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-2.7%Negative MonthJan 2026: -2.74%-3.0%Negative MonthFeb 2026: -3.03%+10.2%Positive MonthMar 2026: +10.19%+10.5%Positive MonthApr 2026: +10.51%+7.0%Positive MonthMay 2026: +7.02%-1.4%Neutral MonthJun 2026: -1.43%-4.7%*Negative MonthJul 2026: -4.69%β€”β€”β€”β€”β€”
2025+3.9%Positive MonthJan 2025: +3.86%-9.3%Negative MonthFeb 2025: -9.34%+7.7%Positive MonthMar 2025: +7.69%-2.6%Negative MonthApr 2025: -2.63%+24.5%Positive MonthMay 2025: +24.54%+10.8%Positive MonthJun 2025: +10.82%-2.8%Negative MonthJul 2025: -2.81%-1.2%Neutral MonthAug 2025: -1.21%-4.5%Negative MonthSep 2025: -4.46%+13.4%Positive MonthOct 2025: +13.44%-6.1%Negative MonthNov 2025: -6.11%+2.7%Positive MonthDec 2025: +2.72%
2024+7.7%Positive MonthJan 2024: +7.68%+12.8%Positive MonthFeb 2024: +12.80%-0.6%Neutral MonthMar 2024: -0.63%+14.5%Positive MonthApr 2024: +14.55%-3.8%Negative MonthMay 2024: -3.83%+10.1%Positive MonthJun 2024: +10.10%+12.7%Positive MonthJul 2024: +12.68%+25.3%Positive MonthAug 2024: +25.28%+4.4%Positive MonthSep 2024: +4.44%+11.1%Positive MonthOct 2024: +11.15%+5.1%Positive MonthNov 2024: +5.09%-59.6%Negative MonthDec 2024: -59.63%
2023-15.4%Negative MonthJan 2023: -15.38%+0.8%Neutral MonthFeb 2023: +0.83%-3.9%Negative MonthMar 2023: -3.91%+19.0%Positive MonthApr 2023: +19.01%+5.8%Positive MonthMay 2023: +5.76%+19.5%Positive MonthJun 2023: +19.46%+9.7%Positive MonthJul 2023: +9.73%-6.2%Negative MonthAug 2023: -6.22%+14.8%Positive MonthSep 2023: +14.76%-6.2%Negative MonthOct 2023: -6.20%+2.1%Positive MonthNov 2023: +2.10%+33.3%Positive MonthDec 2023: +33.25%
2022-11.8%Negative MonthJan 2022: -11.80%-18.9%Negative MonthFeb 2022: -18.88%+8.3%Positive MonthMar 2022: +8.33%-5.3%Negative MonthApr 2022: -5.30%+1.2%Neutral MonthMay 2022: +1.17%-0.3%Neutral MonthJun 2022: -0.35%+0.1%Neutral MonthJul 2022: +0.14%-0.1%Neutral MonthAug 2022: -0.14%+0.5%Neutral MonthSep 2022: +0.54%-7.0%Negative MonthOct 2022: -6.99%+8.9%Positive MonthNov 2022: +8.85%+3.6%Positive MonthDec 2022: +3.62%
2021β€”β€”β€”β€”β€”-4.5%Negative MonthJun 2021: -4.50%+1.6%Neutral MonthJul 2021: +1.55%-20.4%Negative MonthAug 2021: -20.38%-4.0%Negative MonthSep 2021: -4.04%-9.3%Negative MonthOct 2021: -9.27%-8.6%Negative MonthNov 2021: -8.65%-8.5%Negative MonthDec 2021: -8.47%
AvgΒ±SD-3.7%Β±8.8%-3.5%Β±10.5%+4.3%Β±5.6%+7.2%Β±9.6%+6.9%Β±9.6%+5.7%Β±8.4%+2.8%Β±6.3%-0.5%Β±14.8%+2.2%Β±7.1%+0.4%Β±9.8%+0.3%Β±6.6%-5.7%Β±30.3%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 1.155x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή2.14 K Crβ–² 14.6%
EBITDA Growthβ€”
Net Profitβ‚Ή2.89 K Crβ–² 6313.3%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–Ό 881.8%
Revenue CAGR 5Y2.0%
EBITDA CAGR 5Y-1.7%
Net Profit CAGR 5Y-17.8%
NP Growth 1Y6313.3%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή2.14 K Crβ€”β‚Ή2.89 K Crβ€”β€”90.4%14.6%6313.3%
Mar 2024β‚Ή1.87 K Crβ€”β‚Ή45.00 Crβ€”β€”1.3%0.6%800.0%
Mar 2023β‚Ή1.85 K Crβ€”β‚Ή5.00 Crβ€”β€”0.1%-6.3%-97.2%
Mar 2022β‚Ή1.98 K Crβ€”β‚Ή180.00 Crβ€”β€”5.3%6.5%130.8%
Mar 2021β‚Ή1.86 K Crβ€”β‚Ή78.00 Crβ€”β€”2.4%9.8%-35.0%
Mar 2020β‚Ή1.69 K Crβ€”β‚Ή120.00 Crβ€”β€”3.8%10.1%9.1%
Mar 2019β‚Ή1.54 K Crβ€”β‚Ή110.00 Crβ€”β€”3.4%4.6%-87.7%
Mar 2018β‚Ή1.47 K Crβ€”β‚Ή892.00 Crβ€”β€”28.2%6.4%718.3%
Mar 2017β‚Ή1.38 K Crβ€”β‚Ή109.00 Crβ€”β€”3.4%-36.1%-16.2%
Mar 2016β‚Ή2.16 K Crβ€”β‚Ή130.00 Crβ€”β€”4.1%132.7%-75.6%

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2014 15mMar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales1,0649292,1621,3821,4701,5371,6921,8581,9791,8541,8662,1392,128
Total Expenses9147951,8941,2551,2711,4021,4871,6981,9021,7551,7151,8771,856
EBIT / Operating Profit15013426812719913520515977100151263271
OPM %14%14%12%9%14%9%12%9%4%5%8%12%13%
Other Income4,6146198215486011193117123681222,87330
Finance Costs10534103728254676574139139146123
Depreciation & Amortisation4749103707883949910494878587
Profit Before Tax4,61266914513989910913611222-65462,90591
Tax %24%20%10%22%1%-1%12%30%-738%-107%3%1%-
Net Profit / PAT3,513532130109892110120781805452,88676
EPS (β‚Ή)589.4289.3214.5812.1499.6212.3313.428.7220.070.524.85313.048.30
Dividend Payout %86%121%34%37%2%24%104%29%0%289%52%1%-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
STRIDES PHARMA SCIENCE LIMITEDthis co.β‚Ή8.55 K Crβ‚Ή2.14 K Cr112.002.6835.5414.6%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of STRIDES PHARMA SCIENCE LIMITED and the metrics that matter.

Browse the full Equiscale Academy